Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development

Reuters

06-03

Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) to advance the development of botensilimab and balstilimab (BOT/BAL). The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603011983) on June 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540277596"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540277596\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540277596?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540277596","market":"us","top_or_hot":-1,"title":"Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) to advance the development of botensilimab and balstilimab (BOT/BAL). The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603011983) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-03 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) to advance the development of botensilimab and balstilimab (BOT/BAL). The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603011983) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL1zrrq7:1","article_id":"2540277596","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540277596","pubTimestamp":1748948445,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Agenus Inc. , a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd.  to advance the development of botensilimab and balstilimab . The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Agenus Inc.和Zydus Lifesciences宣布开展1.41亿美元战略合作，促进癌症免疫疗法开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus Inc. and Zydus Lifesciences Announce $141M Strategic Collaboration to Boost Cancer Immunotherapy Development\n    \n\n        Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, has announced a strategic collaboration with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) to advance the development of botensilimab and balstilimab (BOT/BAL). The agreement includes a $75 million upfront payment to Agenus for transferring manufacturing assets, with potential additional payments up to $50 million contingent on BOT/BAL production orders. Zydus will gain exclusive licensing rights for BOT/BAL in India and Sri Lanka and make a $16 million equity investment in Agenus. This partnership aims to accelerate BOT/BAL clinical development, expand global manufacturing capabilities, and improve patient access to oncology therapeutics. Agenus will leverage Zydus' facilities in Emeryville and Berkeley, CA, for manufacturing, positioning these as flagship U.S. sites for biologics contract manufacturing services.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603011983) on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}